> Detailanzeige

Gaertner, Jan [Verfasser:in]; Stamer, Ulrike M. [Verfasser:in]; Remi, Constanze [Verfasser:in]; Voltz, Raymond [Verfasser:in]; Bausewein, Claudia [Verfasser:in]; Sabatowski, Rainer [Verfasser:in]; Wirz, Stefan [Verfasser:in]; Müller-Mundt, Gabriele [Verfasser:in]; Simon, Steffen T. [Verfasser:in]; Pralong, Anne [Verfasser:in]; Nauck, Friedemann [Verfasser:in]; Follmann, Markus [Verfasser:in]; Radbruch, Lukas [Verfasser:in]; Meißner, Winfried [Verfasser:in]

Metamizole/dipyrone for the relief of cancer pain

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Metamizole/dipyrone for the relief of cancer pain : A systematic review and evidence-based recommendations for clinical practice
  • Beteiligte: Gaertner, Jan [Verfasser:in]; Stamer, Ulrike M. [Verfasser:in]; Remi, Constanze [Verfasser:in]; Voltz, Raymond [Verfasser:in]; Bausewein, Claudia [Verfasser:in]; Sabatowski, Rainer [Verfasser:in]; Wirz, Stefan [Verfasser:in]; Müller-Mundt, Gabriele [Verfasser:in]; Simon, Steffen T. [Verfasser:in]; Pralong, Anne [Verfasser:in]; Nauck, Friedemann [Verfasser:in]; Follmann, Markus [Verfasser:in]; Radbruch, Lukas [Verfasser:in]; Meißner, Winfried [Verfasser:in]
  • Erschienen: London: Sage, [2019]
  • Erschienen in: Palliative medicine ; 31,1 (2017), Seite 26-34
  • Sprache: Englisch
  • DOI: 10.1177/0269216316655746
  • Schlagwörter: Palliativmedizin ; palliative care ; Neoplasmen ; Überprüfung ; non-steroidal anti-inflammatory agents ; neoplasms ; review ; Dipyron ; Schmerzbehandlung ; Dipyrone ; pain management ; nichtsteroidale entzündungshemmende Mittel
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: Background: Dipyrone (metamizole) is one of the most widely used non-opioid analgesics for the treatment of cancer pain.Aim: Because evidence-based recommendations are not yet available, a systematic review was conducted for the German Guideline Program in Oncology to provide recommendations for the use of dipyrone in cancer pain. Design: First, a systematic review for clinical trials assessing dipyrone in adult patients with cancer pain was conducted. Endpoints were pain intensity, opioid-sparing effects, safety, and quality of life.Data sources: The search was performed in MedLine, Embase (via Ovid), and the Cochrane Library (1948–2013) and additional hand search was conducted. Finally, recommendations were developed and agreed in a formal structured consensus process by 53 representatives of scientific medical societies and 49 experts.Results: Of 177 retrieved studies, 4 could be included (3 randomized controlled trials and 1 cohort study, n = 252 patients): dipyrone significantly decreased pain intensity compared to placebo, even if low doses (1.5–2 g/day) were used. Higher doses (3 × 2 g/day) were more effective than low doses (3 × 1 g/day), but equally effective as 60 mg oral morphine/day. Pain reduction of dipyrone and non-steroidal anti-inflammatory drugs did not differ significantly. Compared to placebo, non-steroidal anti-inflammatory drugs, and morphine, the incidence of adverse effects was not increased.Conclusion: Dipyrone can be recommended for the treatment of cancer pain as an alternative to other non-opioids either alone or in combination with opioids. It can be preferred over non-steroidal anti-inflammatory drugs due to the presumably favorable side effect profile in long-term use, but comparative studies are not available for long-term use.
  • Zugangsstatus: Freier Zugang
  • Rechte-/Nutzungshinweise: Urheberrechtsschutz